Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + capecitabine + lenvatinib
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This drug combination is a multi-modality therapeutic regimen being evaluated for the second-line treatment of advanced or metastatic biliary tract carcinoma (BTC). It consists of **irinotecan liposome**, a nanoparticle formulation of the topoisomerase I inhibitor irinotecan designed for prolonged systemic exposure and enhanced tumor accumulation; **capecitabine**, an oral fluoropyrimidine carbamate that functions as a cytotoxic prodrug of 5-fluorouracil; and **lenvatinib**, an oral multi-kinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. The regimen, studied in clinical trials led by investigator Yunpeng Liu, aims to leverage the synergistic effects of cytotoxic chemotherapy and targeted anti-angiogenic therapy to overcome resistance in refractory biliary tract cancers.
- Other names
- Irinotecan hydrochloride liposome injection + Capecitabine + LenvatinibIrinotecan liposome plus Capecitabine and Lenvatinib
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on irinotecan liposome + capecitabine + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + capecitabine + lenvatinib.